Highlights

  • Cochlear (ASX:COH) reported FY26 underlying net profit of A$322.4 million, down from the prior year, while second-half momentum improved.
  • Implant volumes increased 5% to 56,692 units, supported by continued adoption of the Nucleus Nexa System.
  • Services Revenue rose 6% in constant currency to A$635 million, strengthening the Recurring Revenue base.
  • FY27 guidance points to a return to Earnings growth, with investors watching margins, Nexa adoption and implant demand.

Cochlear (ASX:COH) delivered a challenging FY26 result, with lower profit and a reduced dividend, but the market focused on improving operational momentum and a more constructive FY27 outlook. The company's second-half recovery, rapid adoption of the Nucleus Nexa System and continued growth in services revenue have reinforced the longer-term Investment case. The key question now is whether these improvements can translate into sustainable earnings growth and Margin recovery.

Why a weaker result sparked a relief rally

Cochlear's FY26 result presented a mixed picture.

Underlying net profit declined approximately 22% to A$322.4 million from A$414.5 million a year earlier, while statutory profit declined around 62% to A$147.3 million.

Despite the weaker earnings result, investor sentiment improved as the company finished the year at the upper end of its revised guidance range and showed stronger momentum in the second half.

Revenue growth accelerated during the second half, and management's FY27 outlook pointed toward a return to earnings growth.

The market reaction therefore reflected expectations around future improvement rather than the FY26 headline numbers alone.

Under the bonnet: revenue pressure, one-offs and margin impact

Revenue was A$2.343 billion, down around 1% on a reported basis, while constant-currency growth was approximately 2%.

The second half was stronger, with constant-currency revenue growth accelerating to 6%.

Profitability was affected by several factors.

A stronger Australian dollar reduced Underlying Profit by approximately A$24 million.

Gross margin declined to 71% from 74%, while Research and Development investment increased 15%.

The statutory result was also affected by several non-recurring items, including around A$109.1 million of non-cash investment write-downs, primarily related to Epiminder, along with cloud-computing costs and transitional restructuring expenses.

Reflecting the weaker earnings outcome, Cochlear reduced its final Dividend to A$1.30 per share, lowering the full-year payout.

The Volume story still works — and Nexa gains momentum

While profitability was under pressure, operational indicators were more constructive.

Cochlear implant volumes increased 5% to 56,692 units.

Implant revenue was broadly flat in constant currency at around A$1.4 billion, reflecting a combination of volume growth, product mix and pricing effects.

The key product development was the continued rollout of the Nucleus Nexa System.

By June 2026, Nexa represented more than 95% of developed-market implant sales and supported an average price increase of approximately 3%.

Services revenue, which includes upgrades and recurring support activities, increased 6% in constant currency to A$635 million.

Developed-market services revenue grew 13%, highlighting the value of Cochlear's expanding installed base.

Acoustics revenue increased 1% to A$273 million following a weaker first half.

Free Cash Flow more than doubled to A$264 million, improving financial flexibility.

What is driving the stock

Cochlear (ASX:COH) is generally valued as a high-quality healthcare technology company, meaning investor expectations are closely linked to growth visibility and execution.

FY26 challenged confidence after earlier earnings pressure, but the stronger second half and FY27 outlook helped shift attention back toward the longer-term opportunity.

Three factors remain central.

First is implant demand. Cochlear's installed base continues to expand, supporting future upgrades and service revenue.

Second is Nexa. The product rollout provides a potential pricing and technology advantage while supporting a new product cycle.

Third is services growth. The recurring nature of upgrades and support revenue provides greater earnings stability compared with one-off implant sales.

However, Cochlear continues to trade on expectations of long-term quality, leaving limited room for operational disappointment.

The growth story: an under-penetrated global market

The long-term opportunity remains linked to the global under-treatment of severe-to-profound hearing loss.

Cochlear remains a leading global provider of cochlear implant technology, competing with companies including Sonova's Advanced Bionics and MED-EL.

Large numbers of potential implant recipients remain untreated, particularly among ageing populations in developed markets and expanding healthcare systems globally.

The Nucleus Nexa System provides a multi-year product cycle and supports future connected-health developments and upgrades.

Each new implant recipient also expands the long-term services opportunity, creating recurring revenue potential through upgrades and ongoing support.

Research and development investment remains focused on improving technology and maintaining product differentiation.

If FY26 represents the low point in earnings momentum, the combination of implant growth, Nexa adoption and services expansion could support a renewed growth phase.

The risks

The recovery outlook still depends on several factors.

Cochlear's medium-term margin target of 18% remains above the 14% net margin achieved in FY26, meaning investors are expecting meaningful operational improvement.

Currency movements remain an ongoing risk because much of the company's revenue is generated offshore while financial reporting occurs in Australian dollars.

Competition from Advanced Bionics and MED-EL remains significant, while processor-upgrade cycles can create variability in demand.

Emerging-market services revenue declined during the year, and healthcare budgets and reimbursement settings remain important factors.

New product transitions also carry execution risks, including manufacturing, inventory management and customer adoption.

Given the company's premium valuation, slower-than-expected recovery in margins or growth could affect investor sentiment.

What Investors Should Watch Next

FY27 guidance will be the key benchmark.

Management expects underlying net profit of A$330–350 million, supported by low-single-digit constant-currency revenue growth.

The February 2027 half-year result will provide the first major test of whether second-half FY26 momentum has continued.

Investors should monitor:

  • developed-market implant volume trends;
  • Nexa adoption rates;
  • services revenue growth;
  • gross-margin recovery;
  • emerging-market performance;
  • currency movements.

These factors will determine whether Cochlear can move from recovery mode back toward consistent growth.

The Bottom Line

Cochlear (ASX:COH) delivered a weaker FY26 result, with lower profit, reduced dividends and margin pressure.

However, the market reaction reflected improving expectations around the future rather than the past year's performance.

Implant volumes increased, Nexa adoption accelerated, services revenue continued expanding and FY27 guidance points toward renewed earnings growth.

The recovery case is therefore based on execution.

Cochlear must demonstrate that pricing benefits, recurring services growth and margin improvement can offset recent challenges.

The Franchise remains strong, but the next year will determine whether FY26 was simply a difficult transition period or the start of a more meaningful recovery.